CANCER

Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.

PRESS RELEASES

APRIL 18, 2018
 Spotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer

Abstracts for the studies are available online:
Phase 1 Cohort 1: http://www.abstractsonline.com/pp8/#!/4562/presentation/11207
Phase 1 Cohort 2: http://www.abstractsonline.com/pp8/#!/4562/presentation/11208

MARCH 28, 2018
Spotlight Innovation Subsidiary Celtic Biotech Iowa to Present Two Posters at 2018 American Association for Cancer Research (AACR) Annual Meeting

MARCH 10, 2017
Spotlight Innovation Commences Part 2 of Phase I Cancer Trial

NOVEMBER 10, 2016
Spotlight Innovation Subsidiary Celtic Biotech Iowa Receives Approval to Commence Phase I Part 2 Clinical Trial of Crotoxin

NOVEMBER 4, 2016
Spotlight Innovation Expands Its Patent Estate of Snake Venom-Derived Therapeutics